In the era of genomics should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

Authors :: Philippe Montcuquet
Marie-Paule Algros
Loic Chaigneau
Fernando Bazan
Sophie Paget-Bailly
Steven M. Butler
Franck Bonnetain
Erion Dobi
Antoine Thiery-Vuillemin
Cristian Villanueva
Xavier Pivot
Phillip G. Febbo
J.-L. Sautière
Christer Svedman
Laura Mansi
Farid Jamshidian
Source :: Journal of Clinical Oncology. 32:e22085-e22085
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e22085 Background: The Oncotype DX Recurrence Score (RS) assay has been validated for prediction of 10-year risk of distant recurrence and likelihood of benefit from chemotherapy in patients with E...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Tumor size
medicine.diagnostic_test
business.industry
medicine.medical_treatment
Recurrence score
Distant recurrence
Genomics
Surgery
Internal medicine
medicine
In patient
business
Oncotype DX

Full Text Access

Tools